The chemokine CXCL10 is produced by many inflammatory cells found in the diseased lung
and has been implicated in the pathogenesis of chronic obstructive pulmonary disease (…

PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)
exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …

Currently, there are no approved targeted therapies for EGFR Exon20ins–driven NSCLC.
Preclinical data shown here, together with promising clinical activity in an ongoing phase I …

Many cancer therapies cause DNA damage to effectively kill proliferating tumor cells;
however, a major limitation of current therapies is the emergence of resistant tumors following …

Entry into mitosis by mammalian cells is triggered by the activation of the cdc2/cyclin B
holoenzyme. This is accomplished by the specific dephosphorylation of key residues by the …

Demonstration that IκB kinase 2 (IKK-2) plays a pivotal role in the nuclear factor-κB-regulated
production of proinflammatory molecules by stimuli such as tumor necrosis factor (TNF)-α …

9006 Background: Preliminary efficacy was observed with the combination of amivantamab,
an EGFR-MET bispecific antibody, and lazertinib, a 3 rd -generation tyrosine kinase inhibitor…

Recent advances in our understanding of the role of cytokine networks in inflammatory
processes have led to the development of novel biological agents for the treatment of chronic …

Marine natural products provide a rich source of chemical diversity that can be used to design
and develop new, potentially useful therapeutic agents. We report here that scytonemin, a …

9512 Background: EGFR exon20ins-mutated NSCLC is generally refractory to EGFR
tyrosine kinase inhibitors (TKIs) and is associated with poor prognosis. Amivantamab (JNJ-…